What's Hot
View all perspectives
Dr. John Cush RheumNow
3 years 4 months ago
Management of Pain in Spondyloarthritis: Dr. Antoni Chan ( @synovialjoints ) discusses abstract #0360 presented at the #ACR21 annual meeting.
https://t.co/C6QU1J6E18 https://t.co/EAfXarQ976
Dr. John Cush RheumNow
3 years 4 months ago
Iberdomide for Lupus: Dr. Kathryn Dao ( @KDAO2011 ) discusses abstract #1458 presented at the #ACR21 annual meeting.
https://t.co/viLtTG0tzB https://t.co/rdWTXaquDS
Dr. John Cush RheumNow
3 years 4 months ago
JAKi For Refractory Still’s Disease: Dr. Olga Petryna ( @DrPetryna) discusses abstract #0195 presented at the #ACR21 annual meeting.
https://t.co/deSxncZOVP https://t.co/OJWGd4Osc4
On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.
Dr. John Cush RheumNow
3 years 4 months ago
RheumNow’s expanded coverage of #ACR21 is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
A treat-to-target strategy has been shown to improve clinical outcomes in patients with rheumatic diseases like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis including systemic lupus erythematosus. The goal of treatment in SLE is aimed at remission or low disease activity.
Pedro Castillo _Castillo_Pedro
3 years 4 months ago
Additional analysis on Phase 2 trial of Deucravacitinib (Tyk-2 inhibitor) in PsA. n=203 (dose 6mg QD v 12mg QD v Placebo)
🔹Prior-TNF vs TNF-naive: similar
Significant improvement:
🔹ACR 20/50/70 & HAQ-DI
🔹TJC/SJC/enthesitis
https://t.co/RV1zLpkUQe
#ACR21 Abst#1820 @RheumNow
Pedro Castillo _Castillo_Pedro
3 years 4 months ago
Study presented by Dr. Michaela Koehm evaluated benefit of MTX in combination with ustekinmuab in PsA w/1° outcome of non-inferiority to placebo @ DAS28 @ wk 24.
🔹Randomized 173 pts
🔹52 weeks
🔹1° met
(continued below)
https://t.co/65ZXDjG9ur
#ACR21 Abst#L12 @RheumNow https://t.co/KsBbwJuLe8
Pedro Castillo _Castillo_Pedro
3 years 4 months ago
Glucocorticoids (GC) in SLE on Belimumab
🔹Post-hoc, 5 phase 3 trials
🔹1° endpoint >25% pred↘️ to <7.5mg/d
🔹BEL n=1869; Placebo n=1217
🔹Baseline: 88% on GC; mean ~12.3mg/d pred
🔹Endpoint met by 17% BEL and 12% Pbo (p=0.0024)
https://t.co/xp9LamlpHZ
#ACR21 Abst#1283 @RheumNow
sheila RHEUMarampa
3 years 4 months ago
#ICYMI #ACR21
Watch my interview with @LatikaGupta_ as she discusses the CoVAD study.
@RheumNow @APLAR_org @rheumarhyme https://t.co/et0X7ltx3K
Nouf Al hemmadi NoufAhmedAlham2
3 years 4 months ago
The amazing team @RheumNow and Dr.Kavanaugh are reviewing abstracts. #ACR21
https://t.co/kz8Y5mEgPN https://t.co/n0NMQ0P9uU
TheDaoIndex KDAO2011
3 years 4 months ago
My Interview with Dr. Seoyoung Kim
👉🏼why/how she got into research
👉🏼her studies on CV risk w/HCQ, real world evidence CV risk w/Tofacitinib, gout T2T MACE occurrence @rheumnow #acr21
https://t.co/RjW5yfyWF6 via @YouTube
Dr. John Cush RheumNow
3 years 4 months ago
Day 1 Report from #ACR21
The first full day of Abstracts and Presentations from ACR Convergence, the 2021 Virtual meeting, was full of highly engaging sessions, quality posters and unique presentations.
https://t.co/hhuGBe8dwr https://t.co/I5dCzFd9SJ
Poster Hall